Our Services
Our Brands
Upcoming Event: REPROCELL Europe to attend the UK Life Science Trade Mission to Switzerland
14-15 May 2019 / Basel and Geneva, Switzerland
REPROCELL Europe Ltd will accompany the UK’s Department for International Trade and Scottish Development International Life Science Trade Mission to Switzerland.
Upcoming Event: Webinars: CRISPR/Cas9 using SNIPER Technology — Managing Challenging Cases
25 & 30 April 2019
Insights about an approach to shortening the timeline for gene editing projects by streamlining the most time-consuming step of CRISPR/Cas9 experiments: screening clones.
Press Release: REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy
24 April 2019
Announcement of our partnership in India to launch a custom manufacture offering for the synthesis of milli molar scale clinical grade oligonucleotides for gene therapy.
Announcement: REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification
8 April 2019
By achieving this standard, REPROCELL USA Inc. has demonstrated its ability to consistently provide various services and products that consistently meet customer requirements.
Announcement: UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
14 March 2019
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, highlighting REPROCELL’s recent work — combining the ability to access human fresh tissues with clinical data, pharmacology and ‘omics’.
Stem Cells for Autism
3 April 2019
In this post, we highlight recent advancements in stem cells as treatment and study of autism to commemorate World Autism Awareness Day (2 April 2019),
Improving patient outcomes through collaboration
28 March 2019
As part of our collaboration with the Medicines Discovery Catapult (MDC), REPROCELL have pledged to provide custom drug discovery assays using live human tissues.
Spotlight: StemRNA Neuro iPSCs – Human Brain Neurons for Functional Assays
20 March 2019
Human induced pluripotent stem cell (iPSC) derived neural models to study brain disease provide an unlimited resource for disease modelling as well as being a tool for drug screening for effective therapies.
3D epithelial barrier assays in vitro: How to get the best balance between practicability and physiological relevance
13 March 2019
Bio-engineered 3D tissue models using Alvetex Scaffold restore the Z-dimension which is missing in flat-surface cell culture, allowing for the building of mucosal and sub-mucosal compartments in a single model.
Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling
22 February 2019
The conventional drug discovery pathway is a very inefficient process. REPROCELL provides services for generating iPSCs from various tissue sources using our state-of-the-art StemRNA 3rd Gen Reprogramming technology.
Our Popular Products
